Clinical trials: Lymphomas,
Diffuse Large B-cell Lymphoma
Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma
Everolimus is an oral mTOR inhibitor with demonstrated preliminary efficacy and safety in diffuse large B-cell lymphoma (DLBCL) in both preclinical and clinical studies.
- Trial name
- NCT00869999
- Testing
- Everolimus, rituximab
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Massachusetts General Hospital
Mantle Cell Lymphoma
Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma
This is a prospective, open-label, single-arm clinical trial evaluating a treatment strategy for previously untreated Mantle Cell Lymphoma (MCL).
- Trial name
- NCT07261163
- Testing
- Zanubrutinib, Obinutuzumab, Lenalidomide
- Where
- 2 sites in China
- Volunteers
- 37 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
CD20 Positive, Recurrent B-Cell Non-Hodgkin Lymphoma
Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma
This partially randomized phase I trial studies the side effects and best dose of ipilimumab when given together with rituximab in treating patients with B-cell lymphoma that has returned or has not responded to treatment.
- Conditions
- CD20 Positive, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT01729806
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Rituximab
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Lymphoma
Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing
Background: Leukapheresis is a procedure to separate and collect white blood cells. It is the first step in a treatment called CAR (chimeric antigen receptor) T-cell therapy.
- Conditions
- Leukemia, Lymphoma, Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma
- Trial name
- NCT03226704
- Testing
- Leukapheresis
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Down Syndrome, Acute Lymphoblastic Leukemia
ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016
To evaluate the outcome of a prednisolone and low dose methotrexate based protocol in Down syndrome children with ALL (DS-ALL) in an Asia-wide study.
- Conditions
- Down Syndrome, Acute Lymphoblastic Leukemia, Childhood Cancer
- Trial name
- NCT03286634
- Testing
- Daunorubicin, Prednisolone, Vincristine
- Where
- 10 sites in Hong Kong, Japan and 4 more
- Volunteers
- 60 people
- Sponsor
- National Hospital Organization Nagoya Medical Center
Follicular Lymphoma (FL)
A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma
This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma.
- Trial name
- OLYMPIA-2 (NCT06097364)
- Testing
- Odronextamab, Rituximab, Cyclophosphamide
- Where
- 145 sites in United States, Australia and 15 more
- Volunteers
- 733 people
- Sponsor
- Regeneron Pharmaceuticals
Follicular Lymphoma
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
The purpose of this study is to evaluate the effect of the combined treatment of lenalidomide and rituximab in controlling the Follicular Lymphoma disease and also increase the length of response compared to the available…
- Trial name
- RELEVANCE (NCT01476787)
- Testing
- Rituximab, Lenalidomide, Rituximab-CHOP
- Where
- 36 sites in United States, Japan
- Volunteers
- 1,030 people
- Sponsor
- Celgene
Cutaneous T-Cell Lymphoma
Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.
The purpose of this trial is to determine the effect of HuMax-CD4, as a treatment for advanced stage (late stage) cutaneous T-cell lymphoma (CTCL).
- Trial name
- NCT00071084
- Testing
- HuMax-CD4
- Where
- 5 sites in United States, Germany and 2 more
- Volunteers
- 22 people
- Sponsor
- Genmab
Acute Lymphoblastic Leukemia ALL
Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL
This research study is evaluating a drug called ribociclib (LEE011) given in combination with everolimus and other standard of care chemotherapy drugs as a possible treatment for relapsed or refractory ALL.
- Trial name
- NCT03740334
- Testing
- Ribociclib, Dexamethasone, Everolimus
- Where
- 12 sites in United States
- Volunteers
- 45 people
- Sponsor
- Dana-Farber Cancer Institute
Acute Lymphoblastic Leukemia
A Phase II Study of CODOX-M/ IVAC in Relapsed/Refractory ALL
A Phase II Study of CODOX-M/ IVAC in Relapsed/Refractory ALL
- Trial name
- NCT00774332
- Testing
- CODOX-M
- Where
- South Korea
- Volunteers
- 37 people
- Sponsor
- Cooperative Study Group A for Hematology
Advanced Solid Tumors, Lymphomas
Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas
A Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas
- Trial name
- NCT00592163
- Testing
- ZIO-101-C (Darinaparsin)
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Alaunos Therapeutics
Diffuse Large B-Cell Lymphoma
A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.
The purpose of this study is to learn about the effects of two study medicines (maplirpacept [PF-07901801] and glofitamab) when given together for the treatment of diffuse large B-cell lymphoma (DLBCL) that is relapsed or is…
- Trial name
- MAPtivate-6 (NCT05896163)
- Testing
- maplirpacept (PF-07901801), Glofitamab, Obinutuzumab
- Where
- 10 sites in United States, Israel and 2 more
- Volunteers
- 40 people
- Sponsor
- Pfizer
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blasts 5 Percent or More of Bone Marrow Nucleated Cells
EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia
This phase I trial studies the side effects and best dose of recombinant EphB4-HSA fusion protein when given together with cytarabine or vincristine liposomal in treating participants with acute leukemia that has come back or has…
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blasts 5 Percent or More of Bone Marrow Nucleated Cells, Myelodysplastic/Myeloproliferative Neoplasm, Philadelphia Chromosome Positive
- Trial name
- NCT03519984
- Testing
- Cytarabine, Laboratory Biomarker Analysis, Recombinant EphB4-HSA Fusion Protein
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Southern California
Blastoid Variant Mantle Cell Lymphoma, Recurrent Chronic Lymphocytic Leukemia
Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant
This phase II trial studies how well ibrutinib works in treating patients after a donor stem cell transplant for lymphoma that is not responding to treatment or has come back.
- Conditions
- Blastoid Variant Mantle Cell Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Follicular Lymphoma, Recurrent Hodgkin Lymphoma
- Trial name
- NCT02869633
- Testing
- Ibrutinib, Laboratory Biomarker Analysis
- Where
- 5 sites in United States
- Volunteers
- 23 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Acute Lymphoblastic Leukemia
Protocol For the Treatment Acute Lymphoblastic Leukemia With Ph 'Negative in Elderly Patients (> 55 Years)
The protocol objective is providing adequate treatment and based on broad consensus in elderly patients with Acute Lymphoblastic Leukemia (ALL).
- Trial name
- NCT01366898
- Testing
- Dexamethasona, Idarubicine, ARA-C, Methotrexate
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- PETHEMA Foundation
Cancer, Neoplasms
Study of Debio 0932 in Patients With Advanced Solid Tumours or Lymphoma
The purpose of this study is to determine the maximum tolerated dose of Debio 0932 when administered orally, every-other-day or daily during the first 30 days, in patients with solid tumours or lymphoma.
- Conditions
- Cancer, Neoplasms, Solid Tumors, Lymphoma
- Trial name
- NCT01168752
- Testing
- Debio 0932
- Where
- 3 sites in France
- Volunteers
- 81 people
- Sponsor
- Debiopharm International SA
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL.
- Trial name
- NCT03331198
- Testing
- JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib, JCAR017 (lisocabtagene maraleucel) + venetoclax
- Where
- 84 sites in United States, Canada
- Volunteers
- 320 people
- Sponsor
- Juno Therapeutics, a Subsidiary of Celgene
Relapsed Hematologic Malignancy
Extended Analysis for Leukemia/Lymphoma Treatment
Patients with relapsed/ refractory acute leukemia and relapsed/ refractory aggressive lymphoma harboring an activating genetic alteration (gene mutation, gene fusion) or drug-able biomarker / activated signal transduction pathway…
- Trial name
- EXALT (NCT03096821)
- Testing
- ngFDS selected treatment
- Where
- Austria
- Volunteers
- 143 people
- Sponsor
- Medical University of Vienna
Lymphoma
Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma
The goal of this clinical research study is to learn if treatment with two types of chemotherapy combinations can help to control peripheral T-cell lymphoma.
- Trial name
- NCT00290433
- Testing
- Cyclophosphamide, Mesna, Vincristine
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia
Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplantation
This is a new platform in non-myeloablative allogeneic stem cell transplantation to improve survival by harnessing the immunologic potential of donor T-cells to induce and maintain long-term remissions in patients with…
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT00374933
- Testing
- Non-myeloablative allogeneic stem cell transplant with prophylactic activated DLI, "Prophylactic" delayed ADLI, "Prophylactic" delayed activated donor lymphocyte infusion
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.